MPS Limited has completed its strategic acquisition of Unbound Medicine Inc., USA for $15.18 million, marking a transformative entry into the healthcare knowledge management sector. The acquisition was executed through MPS North America LLC, a wholly-owned subsidiary, and positions the company at the intersection of healthcare and artificial intelligence.

Strategic Healthcare Intelligence Platform

Unbound Medicine operates as a leader in healthcare knowledge management with over 20 years of clinical expertise. The platform serves more than 1,000 healthcare facilities and supports over 5 million clinical lookups annually across 50+ evidence-based databases. The company maintains a robust subscription-based recurring revenue model with 97% customer retention rates.

The platform provides end-to-end healthcare knowledge curation and streamlining, enabling foundational education, just-in-time learning, and informed decision-making for clinicians, educators, and students.

Market Opportunity and Growth Potential

The acquisition targets a market with significant growth drivers, including a projected global healthcare AI and knowledge management market reaching $188 billion by 2030. The AI-driven knowledge management subsector specifically is expected to grow from $3 billion to $102 billion by 2034 at a 42% CAGR.

Unbound's platform addresses critical healthcare challenges, particularly the projected deficit of 10 million health workers by 2033. In the U.S. alone, 57% of physicians cite reducing administrative burden as their top priority, creating substantial demand for intelligent healthcare solutions.

Financial Performance and Margin Expansion Strategy

Unbound currently operates with a 14% EBITDA margin, which MPS plans to systematically improve through operational synergies and shared infrastructure.

The margin expansion strategy focuses on shared services implementation, operational efficiency improvements using MPS tools and technology, and infrastructure optimization including cloud services.

Technology Integration and Competitive Advantages

Unbound differentiates itself through several key technological moats:

• Clinical Authority: Partnerships with marquee institutions like Johns Hopkins for specialized tools like the Hopkins Antibiotic Guide
• Workflow Integration: Seamless API integration into hospital Electronic Health Record (EHR) systems
• AI-Native Architecture: Unified platform spanning reference, education, and test prep with proprietary analytics
• Rapid Authoring: AI-powered delivery of tailored solutions faster than legacy competitors

The platform operates three core solutions: Nursing Central for nursing education, uCentral for medical centers, and Society Solutions for professional medical associations.

Cross-Selling and Geographic Expansion

MPS plans to leverage its global presence to expand Unbound beyond North America into Europe, APAC, and the Middle East. The company expects significant revenue growth through geographic expansion and cross-selling opportunities.

Key expansion strategies include:

• Utilizing MPS's established presence in international markets
• Cross-selling MPS solutions to Unbound's customer base
• Marketing Unbound platform to MPS's existing institutional partnerships
• Leveraging AJE's strong presence in China where 70% of revenue comes from universities and medical institutions

Management and Integration

The acquisition maintains operational continuity with minimal management changes. Founder and CEO Bill Detmer transitions to a strategic advisor role, while the existing management team including CTO, Head of Sales, Head of Marketing, and Head of Product continue in their positions. The management team has been provided with phantom options at the MPS level.

Transaction Details

The final transaction value of $15.18 million reflects post-closing adjustments from the initially disclosed $16.5 million. MPS funded the acquisition through INR 42 crores of debt, which the company considers comfortable given its improved balance sheet and reduced DSO from 60 to 45 days.

Source: None/Company/INE943D01017/cb02d392-0286-4f6f-ae3a-68b7e831c1fd.pdf

MPS Limited has announced a strategic investment of $16.5 million in Unbound Medicine and has now scheduled a conference call to discuss the acquisition of Unbound Medicine, Inc., USA. The company has formally notified stock exchanges about the conference call scheduled for February 18, 2026, marking a significant development in its North American healthcare technology expansion.

Conference Call Details

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, MPS Limited has scheduled a conference call to discuss the acquisition of Unbound Medicine, Inc., USA by MPS North America LLC, a wholly-owned subsidiary of the company.

Investment Structure and Strategic Approach

The $16.5 million investment combines both debt and equity components, providing MPS with a balanced financial structure for this strategic partnership. This mixed financing approach allows for optimal capital deployment while maintaining strategic flexibility in the partnership with Unbound Medicine.

Management Participation

Mr. Rahul Arora, Chairman and CEO, along with the senior management team of MPS Limited will be present to address the conference call. The company has provided multiple dial-in numbers including universal dial-in numbers, India national toll-free numbers, and international toll-free numbers for various countries including USA, UK, Singapore, Hong Kong, Australia, China, and Germany.

Strategic Implications

This acquisition represents MPS Limited's commitment to strengthening its foothold in the North American healthcare technology landscape through its subsidiary MPS North America LLC. The mixed debt-equity investment structure provides both companies with the financial flexibility needed to pursue aggressive growth strategies while maintaining operational independence. The partnership is expected to enhance both companies' competitive positioning in the rapidly evolving healthcare technology market.